Delivery Order SPE2DB25D3110-SPE2DB25FTEDC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,214.05 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90s, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $1,845.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 11, 2025, with completion targeted for August 12, 2025. This non-set-aside competitive award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- The Defense Logistics Agency awarded a delivery order valued at $6,539.63 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units. The contract employs firm fixed price pricing and carries an ultimate completion date of August 25, 2025, just three days after the award date of August 22, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,733.29 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count bottles) under a firm fixed-price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary...
- The Defense Logistics Agency awarded a delivery order valued at $6,356.18 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Valsartan-HCZ 320-25 mg tablets (90-count) with a ceiling value of $3,727.23. This is a firm fixed price, non-set-aside delivery order that represents a single transaction under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $3,286.65 to AmerisourceBergen Drug Corp for 90-count bottles of Valsartan-HCTZ 320-25 mg tablets. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $10,187.12 delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The contractor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at this same location. This award falls...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEDCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,971.06 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets in quantities of 90 units. This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant position within the federal medical procurement landscape, particularly for military and veteran healthcare systems. The SPE2DX contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The company's federal contract portfolio demonstrates consistent capability to meet procurement requirements through open competition, with delivery orders covering multiple therapeutic domains across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 8/19/25 |